Nick Ziogas, M.D. is an Assoc. Vice President, Clinical Design, Neuroscience at Eli Lilly and Company. He oversees the design and implementation of Phase 1-3 neuroscience clinical trials, focusing on innovative therapies for neurological diseases in order to advance patient care.

Before Lilly, Nick was a Global Clinical Development Leader, Alzheimer's disease at Biogen where he was leading clinical development of Alzheimer's disease investigational drugs, focusing on BIIB080, an antisense oligonucleotide that reduces the production of tau protein and its accumulation in brain cells, potentially slowing the progress of Alzheimer's disease. In addition, he has led the development of multiple programs in Biogen's pipeline, from pre-clinical programs targeting genetic neurodegenerative diseases to Ph3 clinical trials and at Bristol Myers Squibb where he was Global Clinical Development Leader, Neuroscience,  leading clinical development of investigational drugs in neurodegenerative diseases.

Prior to leading clinical development programs at Lilly, Bristol Myers Squibb and Biogen, he was a physician-scientist at Johns Hopkins University School of Medicine, where his research focused on elucidating the neuropathological mechanisms of neurodegenerative diseases.

Nick was born in Thessaloniki, Greece, and earned his M.D. from the Aristotle University of Thessaloniki, followed by a neuropathology fellowship at Johns Hopkins University School of Medicine in Baltimore, MD. He is currently living in Boston, MA.